Daybue has now been on the market about 1 year and it's most recent quarters sales of ~$85m is a 10% increase on last quarter.If growth continues at this (lower guidence) level this would still be an annual growth rate of 50%.
At this growth rate it would take approximately 3 years to reach $250m quarterly sales - which would mean Daybue would achieve blockbuster status with $1b annual revenues (excl ROW) approx 4 years after launch.
Considering new drugs take an average of 5 years to reach peak sales Daybue so far seems to be on track in terms of what is normal.Its not ideal that Acadia downgraded their guidence, but putting this aside the sales trajectory is still that of a successful drug.
Ann: Q2 2024 update, page-36
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 582 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 16.36pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable